SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2006--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for ZEGERID(R) (omeprazole/sodium bicarbonate) Capsules 40 mg/1100 mg and 20 mg/1100 mg, an immediate-release proton pump inhibitor (PPI). ZEGERID Capsules were approved for all of the indications the company was seeking.
